...The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights...
...Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Fujirebio Inc. , Tokyo, Japan Business: Cancer Jaime De Leon farletuzumab Eisai Co. Ltd. Fujirebio Inc. Morphotek...

...to mutations -- including resistance mutations -- as well as changes in the RNA transcriptome. Fujirebio Inc....
...Exosome Diagnostics Inc. Cambridge, Mass. Exotech Bio Inc., Germantown, Md. Exovita Biosciences Inc., Albuquerque, N.M. Fujirebio Inc....

...Cizzle and Fujirebio's Fujirebio Diagnostics Inc. will co-develop Cizzle's blood test that detects a variant of...
...develop a simplified commercial version of the test that can be used in clinical practice. Fujirebio...
...Cizzle. The companies could not be reached for details. Cizzle Biotechnology Ltd. , York, U.K. Fujirebio Inc....

...Abbott's Architect platform and other diagnostic instruments (see BioCentury, March 15, 2010). BG Medicine partner Fujirebio Inc....
...ARCHITECT Galectin-3 test after FDA requested additional clinical data information last July. BG Medicine expects Fujirebio...

...BG Medicine disclosed in its 2012 earnings that partner Fujirebio Inc. (Tokyo, Japan) withdrew a 510(k) application...
...in assessing the prognosis of patients diagnosed with chronic heart failure (CHF). BG Medicine said Fujirebio...
...Fujirebio to submit a new 510(k) application next half addressing FDA's questions. BG Medicine said Fujirebio...

...Thermo Fisher and Fujirebio partnered to make Thermo Fisher's Procalcitonin biomarker assay available on Fujirebio's Lumipulse...
...products use chemiluminescent enzyme immunoassay (CLEIA) technology. The partners could not be reached for comment. Fujirebio Inc....

...the Risk of Ovarian Malignancy Algorithm (ROMA) stratification tool in the U.S. The tool combines Fujirebio's...
...commercialize automated versions of the test (see BioCentury, Dec. 22, 2008 & Feb. 2, 2009). Fujirebio Inc....

...FDA granted 510(k) clearance for Fujirebio's HE4 enzyme immunoassay (EIA) to be used in combination with...
...commercialize automated versions of the test (see BioCentury, Dec. 22, 2008 & Feb. 2, 2009). Fujirebio Inc....

...Fujirebio's Fujirebio Diagnostics Inc. unit received 510(k) clearance from FDA for its CYFRA 21-1 EIA assay...
...samples is available in the U.S. for $550 for a kit with a 100 tests. Fujirebio Inc....

...will use the technology to expand its diagnostic test offerings. Financial terms were not disclosed. Fujirebio Inc....